

AD \_\_\_\_\_

Award Number: DAMD17-99-1-9259

TITLE: Molecular Engineering to Retarget Human Cytokines

PRINCIPAL INVESTIGATOR: Michael Rosenblum, Ph.D.

CONTRACTING ORGANIZATION: The University of Texas  
MD Anderson Cancer Center  
Houston, Texas 77030

REPORT DATE: July 2000

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

DTIC QUALITY INSPECTED 4

20001124 051

# REPORT DOCUMENTATION PAGE

OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY (Leave blank)</b>		<b>2. REPORT DATE</b> July 2000	<b>3. REPORT TYPE AND DATES COVERED</b> Annual (1 Jul 99 - 30 Jun 00)	
<b>4. TITLE AND SUBTITLE</b> Molecular Engineering to Retarget Human Cytokines			<b>5. FUNDING NUMBERS</b> DAMD17-99-1-9259	
<b>6. AUTHOR(S)</b> Michael Rosenblum, Ph.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> The University of Texas MD Anderson Cancer Center Houston, Texas 77030  <b>E-MAIL:</b> mrosenblum@mdanderson.org			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for public release; distribution unlimited				<b>12b. DISTRIBUTION CODE</b>
<b>13. ABSTRACT (Maximum 200 Words)</b>  Overexpression of HER2/ <i>neu</i> in breast cancer is one mechanism responsible for cellular progression of the neoplastic phenotype. Overexpression of HER2/ <i>neu</i> appears to result in reduced sensitivity to the cytotoxic effects of tumor necrosis factor (TNF) and reduced sensitivity to immune effector killing. The single-chain antibody sfv23 recognizes the cell-surface domain of HER2/ <i>neu</i> . The cDNA was fused to the cDNA encoding human TNF and cloned into an expression plasmid. The fusion protein was expressed and purified by ion exchange chromatography. SDS-PAGE demonstrated a single band at the expected molecular weight (43 kDa). Western analysis confirmed the presence of both the antibody component and the TNF component. The construct was shown to have biological activity similar to that of authentic TNF (S.A. 420 nM) against L-929 cells. The scfv23/TNF construct bound to SKBR-3 (HER2 positive) but not to A-375 human melanoma (HER2 negative) cells. Cytotoxicity studies against breast carcinoma cells (SKBR-3-HP) overexpressing HER2/ <i>neu</i> demonstrate that the sfv23/TNF fusion construct was 1000-fold more active than free TNF. These studies suggest that fusion constructs targeting the HER2/ <i>neu</i> surface domain and containing TNF are more effective cytotoxic agents <i>in vitro</i> than native TNF and may be effective against tumor cells expressing intermediate levels of HER2/ <i>neu</i> .				
<b>14. SUBJECT TERMS</b> Fusion Construct, TNF, Her2/neu, cytokines, signal transduction			<b>15. NUMBER OF PAGES</b> 16	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

\_\_\_ Where copyrighted material is quoted, permission has been obtained to use such material.

*WLB* Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

\_\_\_ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.


*WLB* In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

  
PI - Signature

7/27/00  
Date

## TABLE OF CONTENTS

	<u>Page</u>
Cover.....	1
SF 298.....	2
Foreword.....	3
Table of Contents.....	4
Introduction.....	5
Body.....	5-6
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusions.....	8
References.....	8
Appendices.....	8
Abstract.....	9
Publication.....	10-16

## **INTRODUCTION:**

The goal of this research is to understand how overexpression of the HER2/neu protooncogene can modulate cellular response to the cytotoxic effects of the cytokine TNF. In this context, the chimeric fusion construct scfv23/TNF which binds to HER2/neu and contains TNF appears able to overcome HER2/neu mediated resistance to this cytokine. Therefore, this research project focuses on both *in vitro* and *in vivo* development of the scfv23/TNF as a potential therapeutic agent and on understanding the signal transduction events responsible for these observations in breast cancer.

## **BODY:**

**Below are reprinted the first two Objectives from the approved Statement of Work:**

### Technical Objective 1

**We propose to develop genetic fusion constructs of TNF for the purpose of targeting cytotoxic cytokines to human tumors.**

Task 1- months 1-5

Construction of scfv23/TNF in two possible configurations. Confirm by DNA sequence analysis.

Task 2- months 6-9

Express and purify the constructs. Analyze TNF and antibody biological activity.

## Technical Objective 2

**We next propose to examine the in vitro tumor cell binding ability and the antitumor activity of scfv23/TNF against target human tumor cell lines compared to native TNF.**

Task 3- months 10-15

Assess scfv23/TNF cytotoxic activity against TNF sensitive and TNF resistant breast tumor cell lines.

The Appendix contains a galley proof of a manuscript entitled, "A Novel Recombinant Fusion Toxin Targeting HER2/NEU-Over-Expressing Cells and Containing Human Tumor Necrosis Factor". This article is in press in the *International Journal of Cancer* and describes the PCR construction of a chimeric gene encoding scfv23/TNF and insertion of this gene into a bacterial expression vector. The completed vector (designated pCFR-09, Figure 1) was then transfected into bacterial host cells and the recombinant protein was expressed as shown in the manuscript (Figure 2). Western analysis demonstrated the presence of both TNF and the scfv23 antibody components in the construct (Figure 3). The scfv23 component binding HER2 on the surface of breast cancer cells was shown to be intact (Figures 4 and 5). The biological activity of the TNF component was assessed using L-929 cells and was also found to be intact compared to native TNF. Another chimeric construct of scfv23/TNF in an alternate configuration was generated and tested; however, no significant differences were found with this material and a decision was made to focus on one product. Against cells expressing HER2/neu, the construct was shown to be 2,000 fold more active than native TNF. Against cells expressing much higher TNF levels, the construct did not appear to be more active than TNF itself possibly suggesting a difference in the signaling events as a result of HER2 overexpression.

As described, these studies complete Objective 1. Significant progress has also been made towards completion of Objective 2. Thus far, there have been no significant problems of note. Production of the scfv23/TNF at high levels is still a limitation, but progress has been made towards improving both the purification process and the bacterial yield of material.

#### **KEY RESEARCH ACCOMPLISHMENTS:**

- ☐ Generated a scfv23/TNF chimeric construct.
- ☐ Expressed and purified the construct.
- ☐ Demonstrated that the construct is capable of binding Her2/neu and contains active TNF.
- ☐ Demonstrated that the chimeric scfv23/TNF is 2,000 fold more active than TNF on Her2/neu expressing cells.

#### **REPORTABLE OUTCOMES:**

##### **Publications:**

1. M. G. Rosenblum, S. A. Horn, L. H. Cheung, *Int. J. Cancer* **87**, (in press).

##### **Abstracts:**

1. Y. Liu, L. Cheung, M. Rosenblum, *Proceed. Am. Assoc. for Can. Res. Abstract No. 1237*, Vol. 41, 194 (2000).

Funding Applied For Based on this Work:

1. Grant Number: DAMD17-99-1-9259

Investigator: Michael G. Rosenblum, Ph.D.

Amount of Award: \$263,461

Award Period: July 1, 1999 through July 31, 2002

## **CONCLUSIONS:**

In summary, we have generated a unique chimeric fusion construct designated scfv23/TNF which appears to be capable of binding specifically to breast tumor cells expressing HER2/neu. This fusion construct appears to be specifically cytotoxic to HER2/neu expressing tumor cells although the mechanism of action by which this occurs has not been elucidated. This novel construct should be considered for development as a new therapeutic agent for the treatment of breast cancer.

## **REFERENCES:**

Listed under Reportable Outcomes.

## **APPENDICES:**

Attached manuscript and abstract.



# **#1237 TNF FUSION CONSTRUCTS TARGETED TO HUMAN MELANOMA CELLS CAN OVERCOME RESISTANCE TO TNF $\alpha$ .** Yuying Liu, Lawrence Cheung, and Michael Rosenblum, *The Univ of Texas M D Anderson Cancer Ctr, Houston, TX*

Fusion constructs targeting tumor cells have significant potential for directed therapeutic applications in both solid and hematological malignancies. We have developed a fusion construct of TNF $\alpha$  and a single-chain antibody (scfvMEL) recognizing the surface domain of the gp240 antigen present on human melanoma cells. This construct was expressed in bacterial cells and purified to homogeneity using IMAC. The construct (45 kDa) was found to bind specifically to antigen-positive but not antigen-negative cells in culture. The TNF component was biologically active as assessed using the L-929 assay. The fusion construct was more cytotoxic to antigen-positive human melanoma cells than TNF $\alpha$  alone, and was active against antigen-positive, TNF-resistant human melanoma cells. Minimal contact time studies indicate a difference between the scfvMEL/TNF construct and TNF $\alpha$  itself. The augmented cytotoxicity of scfvMEL/TNF was mediated by antibody-specific binding to the cell surface since competition with free ZME reduced cytotoxicity of the construct. Our studies also suggest that the scfvMEL/TNF construct self-associates into a trimeric structure. The scfvMEL/TNF molecule also activated the NF- $\kappa$ B pathway via phosphorylation and proteolytic degradation of I $\kappa$ B in both TNF-sensitive and TNF-resistant human melanoma cells. Animal model studies are in progress to determine the MTD and efficacy against tumor xenografts. These studies are a prelude to proposed clinical trials with this agent in patients with melanoma. Research conducted, in part, by the Clayton Foundation for Research.

# **#1238 CLINICAL PHARMACOLOGY STUDIES OF RHIL-12 ADMINISTERED BY THE INTRAPERITONEAL ROUTE.** Weihe (Wendy) Zhang, Renato Lenzi, Chris D Platoucas, Ralph S Freedman, James L Abbruzzese, and Michael G Rosenblum, *M D Anderson Cancer Ctr, Houston, TX, and Temple Univ Sch of Medicine, Philadelphia, PA*

Recombinant human IL-12 (rhIL-12) is a cytokine of approximately 75 kDa composed of heterodimeric chains of 35 and 40 kDa. The biological properties of rhIL-12 include immunomodulatory and antitumor effects. The antitumor effects of rhIL-12 are proposed to occur as a result of the anti-angiogenic properties of this molecule. As a part of Phase I clinical trials in patients with ovarian cancer, patients received increasing doses of rhIL-12 via an intraperitoneal catheter. Samples of blood and peritoneal fluid (pf) were obtained at various times after administration and frozen until analysis. Levels of rhIL-12, TNF, and IL-1 $\alpha$  were assessed by ELISA assay. Values were subjected to nonlinear regression analysis to obtain standard pharmacokinetic parameters. Immediately after administration, peritoneal fluid concentrations of rhIL-12 ranged from 100-500 pg/ml and persisted for up to 48 hrs in most patients. Initial post-treatment plasma levels of rhIL-12 were 10-100 fold lower than pf and ranged from 0.1-10 pg/ml. At lower doses, levels in plasma and pf followed a variable pattern of clearance over time. Plasma and pf from initial patients showed that levels of TNF- $\alpha$  (1-10 pg/ml) were detectable in 2/4 patients, IL-1 $\alpha$  was detectable in 1/16 patients and IFN- $\gamma$  was found elevated (0.1-1000 pg/ml) in 4/8 patients studied. These studies suggest that increased concentrations of IFN- $\gamma$  and TNF $\alpha$  were the most frequently detected after IL-12 administration and may play a role in the host response mechanism. Further studies on the role of these cytokines in the host response in vivo appear to be warranted.

# **#1239 DIFFERENT INFLUENCE OF INTERLEUKIN-15 ON CYTOTOXIC T-LYMPHOCYTES AND LAK CELLS ON CELL-MEDIATED CYTOTOXICITY IN PANCREATIC CANCER.** Matthias Herbert Peiper, Thomas E Langwieler, Hakim Jaballah, Wolfram T Knoefel, and Jakob R Izbicki, *Univ Hosp Eppendorf, Hamburg, Germany*

Interleukin-15 shares no homology with IL-2, but requires parts of the IL-2 receptor complex for binding and signaling. Its possible role for use in novel immunotherapy approaches remains unclear. This study was performed to evaluate the influence of IL-15 on tumor-specific CTL and LAK cells in pancreatic cancer. LAK cells were generated from buffy coats and high-dose rhIL-2, while CTL were generated from HLA-A2 positive tumor-associated lymphocytes, activated on anti-CD3, educated using repeated autologous tumor cell stimulation. Prior to functional assays using the LDH-method, CTL and LAK cells were incubated with IL-15 (3-100 ng/ml) for 1-3 days. Target cells were autologous and allogeneic pancreatic cancer cells with/without mAb anti-HLA I (W6/32) or mAb anti-HLA-A2 (BB7.2). Normal LAK cells lysed pancreatic cancer cells to a high amount (>55% at 40:1 target/effector ratio (T/R), the lysis was not HLA-A2 restricted ( $P > 0.05$ ). Incubation with IL-15 did not enhance or lower cytotoxicity in LAK cells. TAL-derived CTL lysed autologous and allogeneic tumor cells HLA-A2 restricted with a median of 42% at 40:1 T/R for HLA-A2 positive and 17% for HLA-A2 negative, resp ( $P < 0.001$ ). Incubation with IL-15 enhanced lysis of autologous tumor cells time- and dose-dependent ( $P < 0.05$ ). Lysis of autologous tumor cells was significant higher than of allogeneic tumor cells ( $P < 0.05$ ). Lysis was inhibited in all experiments by incubation with mAb anti-HLA I ( $P < 0.05$ ) and -A2 ( $P < 0.05$ ). Our data demonstrate that there is a different influence of IL-15 on HLA-A2-restricted and tumor-specific CTL vs LAK cells. Further studies on the functional role of IL-15 are necessary to evaluate its distinct mechanisms of action.

# **#1240 ANTIBODY-CYTOKINE FUSION PROTEIN IMMUNOTHERAPY OF PULMONARY METASTASES IN A SYNGENEIC MURINE RENAL CELL CARCINOMA MODEL.** Myra M Mizokami, Peisheng Hu, Leslie A Krawli, and Epstein, *Keck Sch of Medicine, Univ of Southern CA, Los Angeles, CA*

Interleukin-2 (IL-2), tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), and interferon- $\gamma$  (IFN- $\gamma$ ) are important cytokines which may be involved in the natural rejection of tumor. Their efficacy in clinical practice, however, has been limited by dose-limiting toxicities associated with systemic administration. Genetically engineered antibody/cytokine fusion proteins represent a new therapeutic approach which the targeted delivery of potent immunological mediators to tumor foci minimizing systemic toxicity. Our laboratory has developed a novel targeting system known as Tumor Necrosis Therapy, in which monoclonal antibodies to intracellular antigens accessible only in degenerating and necrotic regions of tumors. In our current study, the efficacy of chimeric TNF-3/cytokine fusion proteins were examined in a murine pulmonary metastasis model of renal carcinoma. BALB/c mice were injected intravenously with  $2 \times 10^5$  RENCA cells on day one and received daily treatment with either the antibody fusion protein or relevant control on days five through nine. On day 21, the mice were sacrificed and the number of tumor nodules in the lungs were enumerated after H&E staining. Results demonstrated that non-toxic doses of these fusion proteins significantly decreased the number of lung metastasis compared to control treated with antibody alone. Targeted immunotherapy of malignant disease through the use of antibody-cytokine fusion proteins represents a significant improvement in the delivery of potent immune modulators and in the immunotherapy of metastasis in this syngeneic mouse tumor model.

# **#1241 BIDIRECTIONAL ACTIVATION OF DENDRITIC CELLS AND CD4<sup>+</sup> T CELLS BY A T CELL-DEPENDENT, ACTIVATED T CELL. M Terai, R Yasuda, K Hasumi, Watanabe, D Berd, and T Sato, *Electro-Chemical & Cancer Institute, Tokyo, Japan, and Jefferson Med Coll of Thomas Jefferson Univ, Philadelphia, PA***

There is accumulating evidence that mutual interaction between dendritic cells (DC) and T cells are critically important for the establishment of an effective immune response. Interleukin-12 (IL-12) production by DC triggers the development of Th1 responses and induces production of gamma Interferon (IFN- $\gamma$ ). On the other hand, stimulation of DC with CD40 ligand (CD40L) promotes maturation of DC and induces IL-12 production. We investigated *in vitro* interaction between DC and CD40L-expressing, activated T cells (AT). DC were obtained from peripheral blood monocytes with GM-CSF and IL-4. AT consisted of peripheral blood mononuclear cells activated by PHA and then stimulated with calcium ionophore. The AT produced IFN- $\gamma$  and highly expressed CD40 on the surface. The DC expressed CD40, CD11c, CD54, MHC I, II and CD86. Co-culture of DC and AT induced significant production of IL-12, which was not seen with DC alone. IL-12 production was maximum at a DC:AT ratio of 1:4. IL-12 production and IFN- $\gamma$  production continuously increased through 3 hours of co-culture (1,200 pg/ml and 2,000 pg/ml at 37 hours, respectively). In contrast, the IL-12 level reached a plateau at 18 hours (maximum 700 pg/ml) in control: DC stimulated with LPS without AT. The IFN- $\gamma$  level reached a plateau at 3 hours (maximum 600 pg/ml) with AT alone. These results confirm the importance of mutual interaction between DC and AT and support clinical application of DC and AT therapy.

# **#1242 DEVELOPMENT OF AN ASSAY TO DETECT AN ANTI-HU14.18-IL2 RESPONSE FOLLOWING IN VIVO THERAPY WITH ANTI-GD2 FUSION PROTEIN, HU14.18-IL2.** Amy M Ostendorf, Mark R Albertini, Jacek Gan, Jacquelyn Hank, Stephen D Gillies, and Paul M Sondel, *Lexigen Pharmaceuticals Corp, Lexington, MA, and Univ of Wisconsin-Madison, Madison, WI*

The Hu14.18-IL2 fusion protein (HuFP) consists of a humanized monoclonal antibody (Ab), hu14.18, genetically linked to IL2. The Ab portion of HuFP recognizes GD2, a cell surface disialoganglioside overexpressed in melanoma and certain other tumors. The University of Wisconsin is conducting a Phase I Clinical Trial of HuFP in patients with GD2+ melanomas. We have created an ELISA system to detect anti-HuFP responses in patients receiving HuFP. In this ELISA system, we measure the ability of 12.5 ng/well of HuFP to bind GD2-coated wells. Binding of HuFP to GD2 is quantitated through use of a biotinylated goat anti-human-IL2 Ab followed by addition of an avidin-HRP conjugate and colorimetric detection. This system has been tested using an anti-idiotypic (anti-id) murine Ab that recognizes the antigen binding portion of the HuFP. In order to simulate the possible presence of anti-id Abs in patient serum, the murine anti-id Ab has been mixed with human serum and tested in this ELISA. Dose dependent inhibition of HuFP binding to GD2 was observed using this murine anti-id Ab. We intend to use this assay to evaluate sera from patients receiving HuFP in our clinical trial. Patient sera that contain anti-id Abs that interrupt HuFP-GD2 recognition should be detectable because they inhibit or reduce this interaction. This assay should provide a reproducible means of evaluating patient response to HuFP. The specific molecular nature of any response detected, and its influence on HuFP pharmacokinetics will require further investigation.

# **#1243 PHASE I-II TRIAL OF INTERLEUKIN-2 (IL-2) AND 13-CIS RETINOIC ACID (RA) AS MAINTENANCE THERAPY IN ADVANCED CANCER.** F Recchia, S DeFilippis, M Rosselli, G Saggio, P L Pompili, A Cesta, and S Rea, *F I T, Ita Oncology, Avezzano, Italy, Surg Oncology Univ of L'Aquila, Italy.*

Int. J. Cancer: 87, 000-000 (2000)  
© 2000 Wiley-Liss, Inc.



Publication of the International Union Against Cancer

## A NOVEL RECOMBINANT FUSION TOXIN TARGETING HER-2/NEU-OVER-EXPRESSING CELLS AND CONTAINING HUMAN TUMOR NECROSIS FACTOR

Michael G. ROSENBLUM\*, Shirley A. HORN and Lawrence H. CHEUNG

Immunopharmacology and Targeted Therapy Section, Department of Bioimmunotherapy, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

Over-expression of the proto-oncogene *HER2/neu* in breast cancer and certain other tumors appears to be a central mechanism that may be partly responsible for cellular progression of the neoplastic phenotype. Transfection of mammalian cells and over-expression of *HER2/neu* appears to result in reduced sensitivity to the cytotoxic effects of tumor necrosis factor (TNF) and reduced sensitivity to immune effector killing. The single-chain recombinant antibody sFv23 recognizes the cell-surface domain of *HER2/neu*. The cDNA for this antibody was fused to the cDNA encoding human TNF, and this sFv23/TNF fusion construct was cloned into a plasmid for expression in *Escherichia coli*. The fusion protein was expressed and purified by ion-exchange chromatography. SDS-PAGE demonstrated a single band at the expected m.w. (43 kDa). Western analysis confirmed the presence of both the antibody component and the TNF component in the final fusion product. The fusion construct was tested for TNF activity against L-929 cells and found to have biological activity similar to that of authentic TNF (SA 420 nM). The sFv23/TNF construct bound to SKBR-3 (*HER2*-positive) but not to A-375 human melanoma (*HER2*-negative) cells. Cytotoxicity studies against log-phase human breast carcinoma cells (SKBR-3-HP) over-expressing *HER2/neu* demonstrate that the sFv23/TNF fusion construct was 1,000-fold more active than free TNF. Tumor cells expressing higher levels of *HER2/neu* (SKBR-3-LP) were relatively resistant to both the fusion construct and native TNF. These studies suggest that fusion constructs targeting the *HER2/neu* surface domain and containing TNF are more effective cytotoxic agents *in vitro* than native TNF and may be effective against tumor cells expressing intermediate, but not high, levels of *HER2/neu*. *Int. J. Cancer* 87:000-000, 2000.

© 2000 Wiley-Liss, Inc.

*neu*-transformed cells are resistant to the cytotoxic effects of TNF. In addition, NIH 3T3 cells transfected with *HER2/neu* appear to be resistant to immune effector cell killing mediated by membrane-bound TNF. Since TNF plays a central role in immune surveillance functions (Saks and Rosenblum, 1992), resistance to its cytotoxic effects mediated by *HER2/neu* over-expression in breast cancer may allow transformed cells a growth advantage by escaping host defense mechanisms. To date, there have been few studies aimed at elucidating the biochemical events linking *HER2/neu* signal transduction with TNF signal transduction in breast cancer cells.

Monoclonal antibodies (MAbs) have the potential to serve as targeting vehicles for various classes of therapeutic agents and to be utilized for targeting proteinaceous therapeutic agents such as interleukins, lymphokines, and cytokines (Theuer and Pastan, 1993; Reisfeld *et al.*, 1997). However, there are demonstrated pitfalls of this approach, including heterogenous tumor antigen expression *in vivo*; pharmacological barriers resulting in poor tumor penetration by the antibody, due in part to antibody size; antigenicity of antibodies and antibody constructs, leading to reduced utility. Molecular approaches to address these concerns have provided numerous options to reconfigure natural antibodies while simultaneously incorporating effector or toxin functions within the same molecule (Colnaghi *et al.*, 1993; Hand *et al.*, 1994). Studies by our group and by others initially demonstrated the utility of chemical constructs of antibodies and cytokines such as  $\alpha$ -IFN (Ozzello *et al.*, 1994; Zuckerman *et al.*, 1987). Reisfeld *et al.* (1997) have studied fusion constructs of full-length antibodies in which framework domains are replaced by human cytokines (described as immunocytokines). Clinical trials of these recombinant constructs are now in progress (Gillies *et al.*, 1991; Reisfeld and Gillies, 1996a,b).

Single-chain antibodies (scFvs or sFvs), incorporating the binding characteristics of the parent immunoglobulin, consist of the antibody VL and VH domains (the Fv fragment) linked by a designed flexible peptide tether. Compared to intact IgGs, scFvs have the advantages of smaller size (approx. 30 kDa) and structural simplicity (single-chain vs. 4 chains) with comparable antigen-binding affinities, and they are more stable than the analogous 2-chain Fab fragments (Pantolino *et al.*, 1991). It has been proposed that the smaller size of scFvs provides better penetration into tumor tissue, improved pharmacokinetics, and a reduction in the immunogenicity observed with *i.v.* administered Fabs (Savage *et al.*, 1993) compared to that of intact murine antibodies. Numerous recombinant antibodies fused to plant or bacterial toxins such as *Pseudomonas* exotoxin, ricin, and gelonin have been reported

The *HER2/neu* proto-oncogene encodes a 185 kDa transmembrane glycoprotein kinase (gp 185) with extensive homology to the epidermal growth factor (EGF) receptor (Shepard *et al.*, 1991; Jardines *et al.*, 1993; King *et al.*, 1985; Schechter *et al.*, 1985; Yamamoto *et al.*, 1986). Transfection studies suggest that *HER2/neu* over-expression may play a direct role in cellular transformation to a neoplastic phenotype (DiFiore *et al.*, 1987; Hudziak *et al.*, 1987). Amplification of the gene and over-expression of the gp 185 protein product have been described in a number of human cancers, including mammary and ovarian carcinomas, gastric tumors, and colon and salivary gland adenocarcinomas (Semba *et al.*, 1985; Yokota *et al.*, 1988). Slamon *et al.* (1987) found *HER2/neu* over-expressed in approximately 30% of 189 primary breast carcinomas examined. Their study demonstrated that over-expression of *HER2/neu* was correlated with poor disease prognosis. Follow-up studies have also suggested that *HER2/neu* cellular expression is associated with a shortened disease-free survival (DFS) (Seshadri *et al.*, 1993; Mansour *et al.*, 1994). Thus, the clinical observations of the importance of *HER2/neu* as a negative prognostic indicator *in vivo* have been repeatedly confirmed by molecular studies demonstrating the central role of this oncogene in promotion of the growth of transformed cells and in increasing their metastatic potential.

One of the key roles this oncogene appears to play is in modulation of the cellular response to cytotoxic cytokines such as tumor necrosis factor (TNF) (Tang *et al.*, 1994; Lichtenstein *et al.*, 1991). A variety of research groups have demonstrated that *HER2/*

Grant sponsor: National Institutes of Health; Grant number: CA 16672; Grant sponsor: Clayton Foundation for Research.

\*Correspondence to: Michael G. Rosenblum, Immunopharmacology and Targeted Therapy Section, Box 044, Department of Bioimmunotherapy, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. Fax: +713-794-4261. E-mail: mrosenbl@notes.mdacc.tmc.edu

Received 17 January 2000; Revised 13 March 2000; Accepted 17 March 2000.

Orig. Op.	OPERATOR:	Session	PROOF:	PE's:	AA's:	COMMENTS	ARTNO:
1st DCT-498, 2nd DCT-498	martink	6	HS/CM				30055

(Preijers, 1993) and are currently undergoing pre-clinical and phase I trials (Theuer and Pastan, 1993; Uckun and Frankel, 1993).

TNF is a cytotoxic polypeptide secreted primarily by activated macrophages (Carswell *et al.*, 1975; Aggarwal *et al.*, 1985), which shares some sequence homology (30%) with another peptide hormone, lymphotoxin (LT or TNF- $\beta$ ) secreted by activated lymphocytes (Rosenblum and Donato, 1989). Purified recombinant human TNF is a single-chain, non-glycosylated polypeptide of m.w. 17.1 kDa. *In vitro*, TNF is cytostatic or cytotoxic to a number of human tumor cells, including SKBR-3 breast carcinoma and A-375 human melanoma. Several groups have demonstrated that human tumor cells can display between 100 and 5,000 TNF receptor sites per cell (Tsujimoto *et al.*, 1985; Sugarman *et al.*, 1985). However, no apparent correlations have been observed between receptor number (or affinity) and the cellular response to the cytotoxic effects of TNF, suggesting that post-receptor signaling events primarily modulate TNF biochemical effects (Nitsu *et al.*, 1985). Cloning and sequencing of the genes encoding the TNF receptor have shown that 2 separate gene products encode TNF-binding activity and appear to be homologous in portions of their extracellular binding domains (Stauber *et al.*, 1988; Hohmann *et al.*, 1989; Loetscher *et al.*, 1990; Schall *et al.*, 1990). This family of molecules appears distinct when compared with sequences defining characteristics of other cytokine or growth factor receptors.

Previous studies in our laboratory have demonstrated that chemical conjugates of human TNF and MAb display significant targeted cytotoxic properties against tumor cells in culture that appear to be far superior to those of native TNF (Rosenblum *et al.*, 1989, 1991, 1995). In addition, studies in xenograft models suggest that these immunocytokines readily accumulate specifically in tumor tissues and demonstrate superior *in vivo* anti-tumor activity compared with native TNF. The purpose of the current study was to extend these original observations by developing a second-generation molecular construct of a recombinant single-chain antibody fused to the TNF molecule, thereby incorporating both antibody and TNF functions within the same molecule. We therefore designed and constructed a recombinant fusion toxin composed of a single-chain antibody targeting the HER2/*neu* proto-oncogene and containing human TNF as a cytotoxic effector molecule. Further studies were designed to examine the biological properties of the fusion construct and its potential for overcoming HER2-mediated resistance to the cytotoxic effects of TNF.

## MATERIALS AND METHODS

The mammalian cell lines SKBR-3 and L-929 were obtained from the ATCC (Rockville, MD). Tryptone and yeast extract were purchased from Difco (Detroit, MI). L-Arabinose was purchased from Sigma (St. Louis, MO). Rabbit polyclonal anti-scFv23 antibody was a generous gift from Oncologix (Gaithersburg, MD). Goat anti-rabbit IgG peroxidase conjugate was obtained from Boehringer-Mannheim (Indianapolis, IN). DTE (dithioerythritol) was purchased from Sigma. Tween-20 came from Fisher Scientific (Pittsburgh, PA). FBS was purchased from Atlanta Biologicals (Norcross, GA).

### sFv23/TNF gene construction

The cDNA encoding the single-chain anti-HER2/*neu* antibody designated sFv23 was obtained from Oncologix, and the cDNA encoding mature human TNF was a generous gift from Dr. J. Klostergaard (M.D. Anderson Cancer Center, Houston, TX). The sFv23/TNF cDNA was constructed by 2-step PCR. The first step consisted of separate PCR amplification of the antibody and TNF coding sequences, utilizing forward and reverse primers for each sequence. The final step consisted of PCR of the sequences, utilizing overlap primers additionally incorporating a flexible tether (G4S) between the antibody and TNF (Fig. 1).

### Expression of fusion protein sFv23/TNF in *Escherichia coli*

Bacterial colonies transfected with the plasmid carrying the sFv23/TNF insert were agitated in a bacterial shaker (Innova 4330;




FIGURE 1 - Design of the sFv23/TNF fusion construct and assembly of the expression vector.

New Brunswick Scientific, Edison, NJ) in 1 l of TYE medium (15 g tryptone, 10 g yeast extract, 5 g NaCl) containing 50  $\mu$ g/ml tetracycline (Sigma) overnight at 37°C at 250 rpm. Bacterial cells were harvested by centrifugation, and the pellet was dispersed into 2 l of fresh TYE. Expression of the target protein was induced by addition of arabinose to a final concentration of 0.1%. The culture was further incubated at 37°C for 2 to 3 h. Cells were collected by centrifugation, resuspended in 80 ml extraction buffer [50 mM Tris-HCl (pH 8), 20 mM EDTA, 0.25 mg/ml lysozyme (Sigma)], and incubated with shaking for 1 hr at room temperature. Triton X-100 and sodium chloride were added to the sample at a final concentration of 2% and 0.5 M, respectively, then incubated for an additional 30 min. After centrifugation, the insoluble fraction of the inclusion bodies was resuspended in 160 ml of 50 mM Tris-HCl (pH 8.0), 20 mM EDTA and sonicated (6  $\times$  20 sec) using a Vir Sonic 300 sonicator (Virtis, Gardiner, NY). Inclusion bodies were then harvested by centrifugation, washed 3 times in the same buffer, and stored at -80°C.

### Protein solubilization, refolding, and purification

Insoluble inclusion bodies were denatured by addition of 6 M guanidine, 100 mM Tris-HCl (pH 7.5), 2 mM EDTA, and 50 mM DTE to make a final concentration of 3 mg/ml protein (as assessed by Bradford protein determination). After a minimum of 2 hr agitation at room temperature, solubilized proteins were diluted 100-fold in refolding buffer [100 mM Tris-HCl (pH 7.5), 2 mM EDTA] and incubated at 12°C for 48 hr. The protein was subsequently bound to a small column containing SP Sepharose Fast Flow Resin (Pharmacia, Gaithersburg, MD). The bound fraction was eluted from the column by addition of 2 M NaCl in 100 mM Tris-HCl (pH 7.5), 2 mM EDTA. Eluted protein fractions were pooled and dialyzed against TBS, and the final product was then further characterized as described below.

### Western methods

Protein samples from the crude extracts of *E. coli*, the purified inclusion bodies, sFv23, and r-TNF were analyzed by SDS-PAGE under reducing conditions. The gel was electrophoretically transferred overnight onto a nitrocellulose transfer and immobilization membrane (Protran; VWR, Sugar Land, TX). The membrane was incubated in 5% BSA/TBS [20 mM Tris-HCl, 137 mM NaCl, and 0.5% Tween 20 (pH 7.6)] and then incubated for 1 hr with anti-sFv23 rabbit polyclonal antibody (1:10,000 dilution in TBS/

Orig. Op.	OPERATOR:	Session	PROOF:	PE's:	AA's:	COMMENTS	ARTNO:
1st DCT-498, 2nd DCT-498	franklin	5					30055

Tween). After successive washing with TBS/Tween-20, the membrane was incubated with goat anti-rabbit IgG horseradish peroxidase (1:5,000 dilution in TBS). The membrane was developed using ECL reagents (Amersham, Arlington Heights, IL) and exposed to X-ray film (Kodak, Rochester, NY).

#### L-929 TNF bioassay

The cytotoxic activity of TNF was determined based on cytotoxicity to the transformed murine fibroblast cell line L-929. Log-phase cells in culture media (RPMI-1640 with 1.5 mM glutamine and 10% FBS) were plated in a 96-well tissue culture plates (Falcon, Lincoln Park, NJ) at a density of  $2 \times 10^4$  cells/well and incubated overnight at 37°C in a 5% CO<sub>2</sub> atmosphere. Then, 200 µl of TNF in PBS starting at 100 units/ml and serial dilutions were added in the presence of actinomycin D (0.5 µg/ml, Sigma). Likewise, serial dilutions of sFv23-TNF were added, and the plate was incubated for 24 hr. Surviving adherent cells were then stained by adding 100 µl of crystal violet [0.5% (w/v) in ethanol]. The stain was incubated on the plates for 0.5 hr, excess stain was removed, the plates were washed with water and allowed to air-dry, and the remaining dye was solubilized by addition of 150 µl of Sorenson's buffer (0.1 M sodium citrate, pH 4.2). Plates were read on a microplate ELISA reader at 540 nm.

#### Binding studies of sFv23/TNF

Binding of sFv23/TNF to SKBR-3 cells was also assessed by ELISA. Log-phase SKBR-3 cells were washed in PBS, and 50,000 cells/50 µl PBS were added to each well of a 96-well tissue culture plate and dried overnight in a 37°C oven. Plates were blocked by addition of 100 µl 5% BSA in PBS. A 50 µl aliquot of sFv23/TNF fusion protein and serial 2-fold dilutions were then added to appropriate wells and incubated for 1 hr at room temperature. After 3 washes (PBS/Tween-20), anti-sFv23 rabbit polyclonal antibody (1 µg/ml in PBSA/Tween-20) was added and incubated for 1 hr. Wells were tapped dry, and 100 µl of horseradish peroxidase-conjugated goat anti-rabbit antibody (Boehringer-Mannheim) were added. Plates were developed by addition of ABTS substrate in 0.1 M citrate buffer (pH 4.2, Sigma) and incubated for 1 hr. Optical density was measured at 405 nm on a Bio-Tek Autoreader.

#### Cytotoxicity of TNF and sFv23/TNF against human breast tumor SKBR-3 cells

Log-phase SKBR-3 cells were diluted to 8,000 cells/100 µl medium. Aliquots (100 µl) were added to 96-well, flat-bottomed

tissue culture plates and incubated for 24 hr at 37°C with 5% CO<sub>2</sub>. Purified sFv 23/TNF or recombinant human TNF was diluted 1:8 in culture medium (McCoy's 5a with 1.5 mM glutamine and 10% FBS). Aliquots of each sample (200 µl) were added to the plate in 2-fold serial dilutions. Plates were further incubated at 37°C, 5% CO<sub>2</sub> for 72 hr. Remaining adherent cells were stained by adding 150 µl crystal violet (Fisher, 0.5% in 20% methanol). Dye-stained cells were solubilized by addition of 150 µl of Sorenson's buffer [0.1 M sodium citrate (pH 4.2) in 50% ethanol], and the plates were read at 540 nm in an ELISA plate reader.

#### RESULTS

PCR products were cloned into a vector for bacterial expression of the recombinant insert. The complete insert was submitted for dideoxynucleotide sequencing (M.D. Anderson Cancer Center Core Sequencing Facility), and the final gene product sequence was confirmed. We utilized a flexible 14-amino acid linker to join the VH and VL regions and a smaller tether (G4S) to link the TNF to the antibody (Fig. 1).

Bacterial expression of the scFv23/TNF fusion construct is shown in Figure 2. After growth and induction with arabinose at 37°C, production of the construct was approximately 5% to 10% of total protein, as assessed by SDS-PAGE. Production of the target fusion construct was estimated to be 25 to 50 mg/l, as assessed by Western analysis. Purification of the soluble protein utilizing ion-exchange chromatography resulted in essentially homogeneous material, as assessed by SDS-PAGE after elution from the exchange resin. Yield of final purified material was approximately 100 µg/l of bacterial culture. Western analysis of the product utilizing antibodies to either TNF or scFv23 (Fig. 3) demonstrated an immunoreactive species with both antibodies at the expected m.w. (43 kDa).

Binding of the sFv23/TNF fusion toxin to adherent SKBR-3 cells was assessed by ELISA using an anti-TNF antibody. Binding of both the native sFv23 single-chain antibody and the sFv23/TNF fusion construct is shown in Figure 4. The binding of both agents was similar and appeared to be dose-dependant. A slightly higher binding of the fusion construct compared to the antibody was noted at the highest concentrations tested. Optimal binding to target cells occurred after incubation with 0.75 µM of the fusion construct (Fig. 5). There was no apparent binding of the construct

#### LANE SAMPLE

- A TNF(17kD) Standard
- B Uninduced sFv23 bacterial lysate
- C Induced sFv23 soluble lysate
- D Affinity (IMAC) resin prior to elution
- E sFv23 eluate from affinity resin
- F Uninduced sFv23-TNF bacterial lysate
- G Induced sFv23-TNF soluble lysate
- H Affinity (IMAC) resin prior to elution
- I sFv23-TNF conjugate from affinity resin
- J Molecular weight markers




FIGURE 2—Expression and purification of both the sFv23 antibody as well as the sFv23/TNF fusion construct from *E. coli*, utilizing an immobilized metal affinity column (IMAC).

Orig. Op.	OPERATOR:	Session	PROOF:	PE's:	AA's:	COMMENTS	ARTNO:
1st DCT-498, 2nd DCT-498	franklim	5					30055

4

ROSENBLUM ET AL.




FIGURE 3—SDS-PAGE and Coomassie staining profiles of bacteria prior to induction (left lane) and following induction (right lane) by addition of IPTG. The position of the scFv23/TNF fusion construct is indicated by the arrow. Western analysis using anti-sFv23 antibody demonstrates reactivity against purified scFv23 antibody (left lane) and the scFv23/TNF fusion construct (right lane); probing the same Western blot with an anti-TNF antibody demonstrates reactivity only with the scFv23/TNF construct.




FIGURE 4—ELISA binding of either sFv23 or sFv23/TNF to SKBR-3-immobilized cells.

to antigen-negative (A-375) cells tested under identical conditions (Fig. 5).

The cytotoxicity of TNF and scFv23/TNF fusion toxin was assessed against murine L-929 cells (data not shown).  $IC_{50}$  values were 1 and 100 pM for native TNF and the antibody/TNF fusion toxin, respectively. This demonstrated approximately a 100-fold decrease in the apparent specific activity for the construct compared to native TNF. This decrease in specific




FIGURE 5—ELISA binding of the scFv23/TNF construct to either antigen-positive SKBR-3 or antigen-negative A-375 cells.

activity could be due to steric hindrance of the antibody interfering with interaction of TNF with its receptor site. Alternatively, since TNF operates optimally as a compact trimer in solution (Rosenblum *et al.*, 1991), the antibody component could also interfere with optimal aggregation of the TNF component in solution.

Two breast carcinoma cell lines, SKBR-3-LP and SKBR-3-HP, were assessed for their relative expression of HER2/*neu* and relative sensitivity to TNF-induced cytotoxicity. The LP variant cell line contained relatively higher levels of HER2/*neu* compared to the HP line (Fig. 6). In addition, the LP line demonstrated much greater resistance to TNF-induced cytotoxic effects. The cytotoxicity of TNF and scFv23/TNF was assessed against log-phase SKBR-3-HP cells; as demonstrated in Figure 7, the  $IC_{50}$  for TNF exceeded 40,000 units/ml, while the scFv23/TNF fusion toxin demonstrated an  $IC_{50}$  value 2,000-fold lower, at approximately 20 units/ml. In contrast, the activity of both TNF and scFv23/TNF was assessed against TNF-resistant cells expressing higher levels of HER2/*neu*. These cells were relatively resistant to the cytotoxic effects of both the scFv23/TNF construct and TNF (Fig. 8). However, the  $IC_{50}$  of TNF against these cells was  $5 \times 10^7$  units/ml, while that of the sFv23/TNF construct was approximately 20-fold lower ( $2 \times 10^6$  units/ml).

F6

F7

F8

Orig. Op.	OPERATOR:	Session	PROOF:	PE's:	AA's:	COMMENTS	ARTNO:
1st DCT-498, 2nd DCT-498	franklin	5					30055




FIGURE 6—Western analysis of 2 variants of SKBR-3 cells (insert) demonstrates that SKBR-3-LP cells express approximately 5-fold lower HER2 protein than SKBR-3-HP cells. Direct comparison of the cytotoxic effects of continuous exposure of various concentrations of TNF demonstrates that the cell line expressing higher levels of HER2 was effectively resistant to TNF while the cells expressing low levels of HER2 were sensitive to the cytotoxic effects of TNF.




FIGURE 7—Cytotoxicity of either TNF or purified sFv23/TNF against log-phase SKBR-3-HP cells in culture. The IC<sub>50</sub> of the sFv23/TNF construct (20 units/ml) was approximately 2,000-fold lower than that of free TNF (4,000 units/ml).

#### DISCUSSION

Numerous groups have examined the biological activity of antibodies chemically conjugated with or genetically fused to numerous human cytokines (Ozzello *et al.*, 1993; Kim *et al.*, 1998). We initially described a novel construct containing recom-

binant human TNF- $\alpha$  chemically conjugated to the murine anti-melanoma MAb ME-018 (Rosenblum *et al.*, 1989, 1991, Rosenblum *et al.*, 1995). Against TNF-sensitive melanoma cells, the construct was several-fold more cytotoxic than free TNF. In addition, this ME/TNF construct was extremely cytotoxic to human melanoma target cells virtually resistant to TNF itself. Follow-up studies demonstrated that the augmented cytotoxicity of the ME/TNF construct was primarily due to the antibody component of the construct binding to target cells. Studies of the ME/TNF construct in xenograft tumor models demonstrated efficient localization within solid tumors after systemic administration, similar to that of the native antibody. Finally, this construct demonstrated impressive cytotoxicity against s.c. xenografts in nude mice. These studies clearly demonstrated that antibody-mediated delivery of agents such as cytotoxic cytokines is feasible and has the potential to modify and enhance the *in vivo* and *in vitro* biological properties of the original cytokine. Since our initial report of antibody/TNF conjugates, other groups have also reported antibody/cytokine constructs with agents such as GM-CSF, IL-2, and lymphotoxin (Reisfeld and Gillies, 1996a,b; Reisfeld *et al.*, 1996; Dreier *et al.*, 1998).

Over-expression of the HER2/*neu* oncogene appears to suppress the cellular cytotoxic response to TNF (Hudziak *et al.*, 1990; Lichtenstein *et al.*, 1990, 1992). However, the cellular mechanisms that could account for this effect have not been elucidated. In a study by Hudziak *et al.* (1990), transformation of NIH 3T3 cells with HER2/*neu* provided cellular resistance to the cytotoxic effects of TNF without appreciably affecting TNF receptor function in the transformants. The current study, examining 2 SKBR-3-selected variant cell lines expressing high and intermediate levels of HER2, demonstrates that the IC<sub>50</sub> values for TNF were >10 and 0.2 nM, respectively (Fig. 5), thus confirming previous observations. Studies by Lichtenstein *et al.* (1990, 1992), utilizing ovarian and breast tumor cell lines over-expressing HER2 to various degrees, also found that resistance to TNF was associated with HER2/*neu* expression. The TNF resistance was not due to reduction in TNF receptor number or signal-transduction events such as MHC expression or ADP-ribose polymerase activity. In another study, these authors demonstrated that increased HER2/*neu* expression also correlated with resistance to killing by lymphokine-activated killer cells (Fady *et al.*, 1993). Therefore, over-expression of HER2 in breast cancer cells appears to provide a distinct growth advantage since the transformed phenotype can effectively escape growth control by soluble cytokine mediators and by immune effector cells empowered to maintain homeostasis.

Orig. Op.	OPERATOR:	Session	PROOF:	PE's:	AA's:	COMMENTS	ARTNO:
1st DCT-498, 2nd DCT-498	franklin	5					30055

The scFv23/TNF construct characterized in our study represents a design improvement over our initial chemical construct of a full-length antibody conjugated to recombinant TNF. Compared to the original construct, the fusion toxin is smaller (50 vs. 190 kDa) and therefore better able to penetrate into solid tumors. In addition, the scFv23/TNF construct is simpler to produce and may be more stable *in vivo* than the original chemical version.

Against TNF-resistant, log-phase SKBR-3 cells, the sFv23/TNF construct was 2,000-fold more active than TNF itself (Fig. 7). These data suggest that the scFv23/TNF fusion construct targeting HER2 may have the ability to overcome cellular resistance mechanisms to TNF induced by intermediate levels of HER2/*neu* but not in the presence of extremely high cellular levels of HER2/*neu*. Against the SKBR-3-LP cell line, which expresses much higher levels of HER2/*neu*, TNF and the sFv23/TNF fusion construct demonstrated similar cytotoxic effects at doses below  $10^6$  units/ml. This suggests that at very high cellular levels of HER2/*neu*, critical signaling pathways for TNF-mediated cytotoxicity may be blocked beyond the ability of this targeted fusion construct to overcome.

Activation of the signal-transduction pathway for TNF is associated with rapid changes in phosphorylation of several substrates, phospholipid metabolism, and interaction with guanine nucleotide binding proteins (G proteins) (Darnay and Aggarwal, 1997). As with other hormone-responsive tissues, the induction of a biological response may be regulated cellularly by expression of appropriate molecules or substrates capable of interaction with a common receptor signaling complex. Therefore, each of these

signaling components may play a role in TNF signal transduction in an appropriate target tissue. Studies in our laboratory (Donato *et al.*, 1991, 1992, 1993) suggest that VEGF receptor phosphorylation status as well as modulation of *c-myc* and ornithine decarboxylase activity play a major role in the early events leading to cytotoxic TNF signal transduction. The ability of HER2/*neu* overexpression to modulate TNF intracellular signaling through any of the biochemical pathways described above and the ability of the scFv23/TNF complex to affect these pathways are not known at this time. It is possible that the ability of the initial ZME/TNF conjugate to overcome resistance to TNF in melanoma cells may be associated with mechanisms underlying the improved cytotoxicity of the scFv23/TNF fusion construct against breast carcinoma cells. Further *in vitro* mechanistic studies are ongoing to examine these potential mechanisms and cytotoxic pathways for the fusion constructs and chemical conjugates compared to native TNF. These studies may provide an additional rationale for the utilization of these agents in a clinical therapeutic setting as well as insight into possible control mechanisms in the TNF cytotoxicity pathway.

#### ACKNOWLEDGEMENTS

We thank Ms. J. Merchant for excellent assistance in the preparation of this report. In addition, we acknowledge NIH Core Grant CA 16672, for support of the DNA Sequencing Facility, and DAMD Grant 17-99-1-9259 supported by US ARMC.

#### REFERENCES

- AGGARWAL, B.B., KOHR, W.J., HASS, P.E., MOFFAT, B., SPENCER, S.A., HENZEL, W.J., BRINGMAN, T.S., NEDWIN, G.E., GOEDEL, D.V., and HARKINS, R.N., Human necrosis factor production, purification and characterization. *J. Biol. Chem.*, **260**, 2345-2354 (1985).
- CARSWELL, E.A., OLD, L.J., KASSEL, R.L., GREEN, S., FIORE, N., and WILLIAMSON, B., An endotoxin-induced serum factor that causes necrosis of tumors. *Proc. nat. Acad. Sci. (Wash.)*, **72**, 3666-3670 (1975).
- COLNAGHI, M.I., MENARD, S., and CANEVARI, S., Evolution of the therapeutic use of new monoclonal antibodies. *Curr. Opin. Oncol.*, **5**, 1035-1042 (1993).
- DARNAY, B.G., and AGGARWAL, B.B., Early events in TNF signaling: a story of associations and dissociations. *J. Leukocyte Biol.*, **61**, 559-566 (1997).
- DIFIORE, P.P., PIERCE, J.H., KRAUS, M.H., SEGATTO, O., KING, R., and AARONSON, S.A., *erbB-2* is a potent oncogene when overexpressed in NIH/3T3 cells. *Science*, **237**, 178-181 (1987).
- DONATO, N.J., ROSENBLUM, M.G., and STECK, P.A., Tumor necrosis factor regulates tyrosine phosphorylation on epidermal growth factor receptors in A431 carcinoma cells: evidence for a distinct mechanism. *Cell Growth Differentiation*, **3**, 259-268 (1992).
- DONATO, N.J., ROTBEIN, J., and ROSENBLUM, M.G., Tumor necrosis factor stimulates ornithine decarboxylase activity in human fibroblasts and tumor target cells. *J. cell. Biochem.*, **46**, 69-77 (1991).
- DONATO, N.J., YAN, D.H., HUNG, M.C., and ROSENBLUM, M.G., Epidermal growth factor receptor expression and function control cytotoxic responsiveness to tumor necrosis factor in ME-180 squamous carcinoma cells. *Cell Growth Differentiation*, **4**, 411-419 (1993).
- DREIER, T., LODE, H.N., XIANG, R., DOLMAN, C.S., REISFELD, R.A., and KANG, A.S., Recombinant immunocytokines targeting the mouse transferrin receptor: construction and biological activities. *Bioconjug. Chem.*, **9**, 482-489 (1998).
- FADY, C., GARDNER, A., GERA, J.F., and LICHTENSTEIN, A., Resistance of HER2/*neu*-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events. *Cancer Immunol. Immunother.*, **36**, 307-314 (1993).
- GILLIES, S.D., YOUNG, D., LO, K.M., FOLEY, S.F., and REISFELD, R.A., Expression of genetically engineered immunocytokines of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. *Hybridoma*, **10**, 347-356 (1991).
- HAND, P.H., KASHMIRI, S.V., and SCHLOM, J., Potential for recombinant immunoglobulin constructs in the management of carcinoma. *Cancer*, **73**, 1105-1113 (1994).
- HOHMANN, H.-P., REMY, R., BROCKHAUS, M., and VAN LOON, P.G.M., Two different cell types have different major receptors for human tumor necrosis factor. *J. Biol. Chem.*, **264**, 14927-14934 (1989).
- HUDZIAK, R.M., LEWIS, G.D., HOLMES, W.E., ULLRICH, A., and SHEPARD, H.M., Selection for transformation and *met* protooncogene amplification in NIH 3T3 fibroblasts using tumor necrosis factor alpha. *Cell Growth Differentiation*, **1**, 129-134 (1990).
- HUDZIAK, R.M., SCHLESSINGER, J., and ULLRICH, A., Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. *Proc. nat. Acad. Sci. (Wash.)*, **84**, 7159-7163 (1987).
- JARDINES, L., WEISS, M., FOWBLE, B., and GREENE, M., *Neu(c-erbB-2/HER2)* and the epidermal growth factor receptor (EGFR) in breast cancer. *Pathobiology*, **61**, 268-282 (1993).
- KIM, Y.S., MASLINSKI, W., ZHENG, X.X., SCHACHTER, A.D., and STROM, T.B., Immunoglobulin-cytokine fusion molecules: the new generation of immunomodulating agents. *Transplant. Proc.*, **30**, 4031-4036 (1998).
- KING, C.R., KRAUS, M.H., and AARONSON, S.A., Amplification of a novel *v-erbB*-related gene in a human mammary carcinoma. *Science*, **229**, 974-976 (1985).
- LICHTENSTEIN, A., BERENSON, J., GERA, J.F., WALDBURGER, K., MARTINEZ-MAZA, O., and BEREK, J.S., Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/*neu* oncogenes. *Cancer Res.*, **50**, 7364-7370 (1990).
- LICHTENSTEIN, A., FADY, C., GERA, J.F., GARDNER, A., CHAZIN, V.R., KELLEY, D., and BERENSON, J., Effects of beta-2 microglobulin anti-sense oligonucleotides on sensitivity of HER2/*neu* oncogene-expressing and nonexpressing target cells to lymphocyte-mediated lysis. *Cell. Immunol.*, **141**, 219-232 (1992).
- LICHTENSTEIN, A., GERA, J.F., ANDREWS, J., BERENSON, J., and WARE, C.F., Inhibitors of ADP-ribose polymerase decrease the resistance of HER2/*neu*-expressing cancer cells to the cytotoxic effects of tumor necrosis factor. *J. Immunol.*, **146**, 2052-2058 (1991).
- LOETSCHER, H., PAN, Y.E., LAHM, H., GENTZ, R., BROCKHAUS, M., RABUCHI, H., and LESSLAUER, W., Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. *Cell*, **61**, 351-359 (1990).
- MANSOUR, E.G., RAVDIN, P.M., and DRESSLER, L., Prognostic factors in early breast carcinoma. *Cancer*, **74**, 381-400 (1994).
- NTSU, Y., WATANABE, N., SONE, H., NEDA, H., YAMAUCHI, N., and URUSHIZAKI, I., Mechanisms of the cytotoxic effect of tumor necrosis factor. *Jpn. J. Cancer Res.*, **76**, 1193-1197 (1985).
- OZZELLO, L., DE ROSA, C.M., BLANK, E.W., CANTELL, K., CERIANI, R.L., and HABIB, D.V., SR., The use of natural interferon alpha conjugated to a

Ed. delete comma per style? Check this out.

Orig. Op.	OPERATOR:	Session	PROOF:	PE's:	AA's:	COMMENTS	ARTNO:
1st DCT-498, 2nd DCT-498	franklin	5					30055

- monoclonal antibody anti mammary epithelial mucin (Mc5) for the treatment of human breast cancer xenografts. *Breast Cancer Res. Treat.*, **25**, 265-276 (1993).
- OZZELLO, L., DE ROSA, C.M., BLANK, E.W., CANTELL, K., CERIANI, R.L., and HABIB, D.V., Sr., Experimental immunotherapy of breast cancer using alpha interferon conjugated to monoclonal antibody Mc5. *Adv. exp. Med. Biol.*, **353**, 35-46 (1994).
- PANTOLINO, M.W., BIRD, R.E., JOHNSON, S., ASEI, E.D., DODD, S.W., WOOD, J.F., and HANDMAN, K.D., Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in *Escherichia coli*. *Biochemistry*, **30**, 10117-10125 (1991).
- PREIJERS, F.W., Rationale for the clinical use of immunotoxins: monoclonal antibodies conjugated to ribosome-inactivating proteins. *Leukemia Lymphoma*, **9**, 293-304 (1993).
- REISFELD, R.A., BECKER, J.C., and GILLIES, S.D., Immunocytokines: a new approach to immunotherapy of melanoma. *Melanoma Res.*, **2**, S99-S106 (1996).
- REISFELD, R.A., and GILLIES, S.D., Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy. *J. clin. lab. Anal.*, **10**, 160-166 (1996a).
- REISFELD, R.A., and GILLIES, S.D., Recombinant antibody fusion proteins for cancer immunotherapy. *Curr. Top. Microbiol. Immunol.*, **213**, 27-53 (1996b).
- REISFELD, R.A., GILLIES, S.D., MENDELSON, J., VARKI, N.M., and BECKER, J.C., Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic *nu/nu* mice by an antibody-lymphotoxin fusion protein. *Cancer Res.*, **56**, 1707-1712 (1996).
- ROSENBLUM, M.G., CHEUNG, L., MUJOO, K., and MURRAY, J.L., An anti-melanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models. *Cancer Immunol. Immunother.*, **40**, 322-328 (1995).
- ROSENBLUM, M.G., CHEUNG, L., MURRAY, J.L., and BARTHOLOMEW, R., Antibody-mediated delivery of tumor necrosis factor (TNF- $\alpha$ ). *Amer. Assoc. Cancer Res.*, Abstract nr. 8802 (1989).
- ROSENBLUM, M.G., CHEUNG, L., MURRAY, J.L., and BARTHOLOMEW, R., Antibody-mediated delivery of tumor necrosis factor (TNF- $\alpha$ ): improvement of cytotoxicity and reduction of cellular resistance. *Cancer Comm.*, **3**, 21-27 (1991).
- ROSENBLUM, M.G., and DONATO, N.J., Tumor necrosis factor- $\alpha$ : a multifaceted peptide hormone. *Crit. Rev. Immunol.*, **9**, 21-44 (1989).
- SAKS, S., and ROSENBLUM, M., Recombinant human TNF- $\alpha$ : preclinical studies and results from early clinical trials. *Immunol. Ser.*, **56**, 567-587 (1992).
- SAVAGE, P., ROWLINSON-BUSZA, G., VERHOEYEN, M., SPOONER, R.A., SO, A., WINDUST, J., DAVIS, P.J., and EPENETOS, A.A., Construction, characterization and kinetics of a single chain antibody recognising the tumour associated antigen placental alkaline phosphatase. *Brit. J. Cancer*, **68**, 738-742 (1993).
- SCHALL, T.J., LEWIS, M., KOLLER, K.J., LEE, A., RICE, G.C., WONG, G.H.W., GATANAGA, T., GRANGER, G.A., LENTZ, R., RAAB, H., KOHR, W.J., and GOEDDEL, D.V., Molecular cloning and expression of a receptor for human tumor necrosis factor. *Cell*, **61**, 361-370 (1990).
- SCHLICHTER, A.L., HUNG, M.-C., VAIDYANATHAN, L., WEINBERG, R.A., YANG-FENG, T. L., FRANK, U., ULLRICH, A., and COUSSENS, L., The *neu* gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. *Science*, **229**, 976-978 (1985).
- SEMBA, K., KAMATA, N., TOYOSHIMA, K., and TAMAMOTO, T., A v-erbB-related protooncogene, c-erbB-2, is distinct from c-erbB-2/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. *Proc. nat. Acad. Sci. (Wash.)*, **82**, 6497-6501 (1985).
- SESHADRI, R., FIRGAIR, F.A., HORSFALL, D.J., MCCAUL, K., SETLUR, V., and KITCHEN, P., Clinical significance of HER-2/*neu* oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. *J. clin. Oncol.*, **11**, 1936-1942 (1993).
- SHEPARD, H.M., LEWIS, G.D., SARUP, J.C., FENDLY, B.M., MANEVAL, D., MORDENTI, J., FIGARI, I., KOTTS, C.E., PALLADINO, M.A., JR., and ULLRICH, A., Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. *J. clin. Immunol.*, **11**, 117-127 (1991).
- SLAMON, D.J., CLARK, G.M., WONG, S.G., LEVIN, W.J., ULLRICH, A., and MCGUIRE, W.L., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/*neu* oncogene. *Science*, **235**, 177-182 (1987).
- STAUBER, G.B., AIYER, R.A., and AGGARWAL, B.B., Human tumor necrosis factor alpha receptor. Purification by immunoaffinity chromatography and initial characterization. *J. Biol. Chem.*, **263**, 19098-19104 (1988).
- SUGARMAN, B.J., AGGARWAL, B.B., HASS, P.E., FIGARCI, I.S., PALLADINO, M.A., and SHEPARD, H.M., Recombinant tumor necrosis factor- $\alpha$ : effect on proliferation of normal and transformed cells *in vitro*. *Science*, **230**, 943-945 (1985).
- TANG, P., HUNG, M.C., and KLOSTERGAARD, J., TNF cytotoxicity: effects of HER-2/*neu* expression and inhibitors of ADP-ribosylation. *Lymphokine Cytokine Res.*, **13**, 117-123 (1994).
- THEUER, C.P., and PASTAN, I., Immunotoxins and recombinant toxins in the treatment of solid carcinomas. *Amer. J. Surg.*, **166**, 284-288 (1993).
- TSUJIMOTO, M., YIP, Y.K., and VILCECK, J., Tumor necrosis factor, specific binding and internalization in sensitive and resistant cells. *Proc. nat. Acad. Sci. (Wash.)*, **82**, 7626-7630 (1985).
- UCKUN, F.M., and FRANKEL, A., The current status of immunotoxins: an overview of experimental and clinical studies as presented at the Third International Symposium on Immunotoxins. *Leukemia*, **7**, 341-348 (1993).
- YAMAMOTO, T., IKAWA, S., AKIYAMA, T., SEMBA, K., NOMURA, N., MIYAJIMA, N., SAITO, T., and TOYOSHIMA, K., Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. *Nature (Lond.)*, **319**, 230-234 (1986).
- YOKOTA, T., YAMAMOTO, T., MIYAJIMA, N., TOTOSHIMA, K., NOMURA, N., SAKAMOTO, H., YOSHIDA, T., TERADA, M., and SUGIMURA, T.M., Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. *Oncogene*, **2**, 283-287 (1988).
- ZUCKERMAN, J.E., MURRAY, J.L., and ROSENBLUM, M.G., Preparation and biological activity of recombinant leukocyte interferon A (rIFN  $\alpha$ A) conjugated to an anti-melanoma murine monoclonal antibody (ZME-1018). *Amer. Assoc. Cancer Res.*, Abstract nr. 1060 (1987).

Orig. Op.	OPERATOR:	Session	PROOF:	PE's:	AA's:	COMMENTS	ARTNO:
1st DCT-498, 2nd DCT-498	franklim	5					30055